Sonoma Pharmaceuticals Inc (SNOA)

$0.195

Live

Insights on Sonoma Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.73M → 3.13M (in $), with an average increase of 13.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -1.48M → -866.0K (in $), with an average increase of 71.4% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 51.6% return, outperforming this stock by 131.2%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 48.2% return, outperforming this stock by 145.7%

Performance

  • $0.19
    $0.21
    $0.20
    downward going graph

    5.6%

    Downside

    Day's Volatility :11.49%

    Upside

    6.24%

    downward going graph
  • $0.12
    $1.52
    $0.20
    downward going graph

    42.05%

    Downside

    52 Weeks Volatility :92.38%

    Upside

    86.84%

    downward going graph

Returns

PeriodSonoma Pharmaceuticals IncIndex (Russel 2000)
3 Months
31.47%
0.0%
6 Months
1.54%
0.0%
1 Year
-78.83%
0.0%
3 Years
-97.46%
-22.6%

Highlights

Market Capitalization
3.1M
Book Value
$0.49
Earnings Per Share (EPS)
-0.82
PEG Ratio
0.0
Wall Street Target Price
3.25
Profit Margin
-41.24%
Operating Margin TTM
-26.9%
Return On Assets TTM
-19.44%
Return On Equity TTM
-82.87%
Revenue TTM
12.3M
Revenue Per Share TTM
1.95
Quarterly Revenue Growth YOY
6.6000000000000005%
Gross Profit TTM
4.5M
EBITDA
-4.3M
Diluted Eps TTM
-0.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.17

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Sonoma Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1566.67%

Current $0.20
Target $3.25

Company Financials

FY18Y/Y Change
Revenue
16.7M
↑ 29.89%
Net Income
-14.3M
↓ 254.5%
Net Profit Margin
-86.01%
↓ 158.32%
FY19Y/Y Change
Revenue
19.0M
↑ 13.88%
Net Income
-11.8M
↓ 17.66%
Net Profit Margin
-62.19%
↑ 23.82%
FY20Y/Y Change
Revenue
18.9M
↓ 0.18%
Net Income
-2.9M
↓ 75.03%
Net Profit Margin
-15.56%
↑ 46.63%
FY21Y/Y Change
Revenue
18.6M
↓ 1.62%
Net Income
-4.6M
↑ 56.65%
Net Profit Margin
-24.77%
↓ 9.21%
FY22Y/Y Change
Revenue
12.6M
↓ 32.21%
Net Income
-5.1M
↑ 10.21%
Net Profit Margin
-40.28%
↓ 15.51%
FY23Y/Y Change
Revenue
13.3M
↑ 5.1%
Net Income
-5.2M
↑ 1.28%
Net Profit Margin
-38.81%
↑ 1.47%
Q3 FY22Q/Q Change
Revenue
3.3M
↑ 44.95%
Net Income
-1.0M
↓ 65.46%
Net Profit Margin
-30.53%
↑ 97.58%
Q4 FY22Q/Q Change
Revenue
2.9M
↓ 11.62%
Net Income
-1.9M
↑ 90.66%
Net Profit Margin
-65.86%
↓ 35.33%
Q1 FY23Q/Q Change
Revenue
3.0M
↑ 2.38%
Net Income
-1.3M
↓ 32.54%
Net Profit Margin
-43.4%
↑ 22.46%
Q2 FY23Q/Q Change
Revenue
3.4M
↑ 13.7%
Net Income
-1.4M
↑ 8.41%
Net Profit Margin
-41.38%
↑ 2.02%
Q3 FY23Q/Q Change
Revenue
2.7M
↓ 20.31%
Net Income
-1.5M
↑ 4.65%
Net Profit Margin
-54.34%
↓ 12.96%
Q4 FY23Q/Q Change
Revenue
3.1M
↑ 14.9%
Net Income
-866.0K
↓ 41.64%
Net Profit Margin
-27.6%
↑ 26.74%
FY18Y/Y Change
Total Assets
19.2M
↓ 24.56%
Total Liabilities
3.9M
↓ 3.67%
FY19Y/Y Change
Total Assets
14.4M
↓ 24.77%
Total Liabilities
4.0M
↑ 2.04%
FY20Y/Y Change
Total Assets
14.6M
↑ 0.78%
Total Liabilities
5.9M
↑ 47.92%
FY21Y/Y Change
Total Assets
15.0M
↑ 2.93%
Total Liabilities
9.6M
↑ 64.34%
FY22Y/Y Change
Total Assets
18.8M
↑ 25.74%
Total Liabilities
10.1M
↑ 5.44%
FY23Y/Y Change
Total Assets
16.2M
↓ 13.87%
Total Liabilities
8.3M
↓ 18.66%
Q3 FY22Q/Q Change
Total Assets
15.0M
↓ 20.6%
Total Liabilities
7.9M
↓ 21.75%
Q4 FY22Q/Q Change
Total Assets
13.9M
↓ 6.91%
Total Liabilities
8.4M
↑ 5.39%
Q1 FY23Q/Q Change
Total Assets
16.2M
↑ 16.54%
Total Liabilities
8.3M
↓ 1.37%
Q2 FY23Q/Q Change
Total Assets
15.9M
↓ 2.08%
Total Liabilities
8.7M
↑ 4.81%
Q3 FY23Q/Q Change
Total Assets
13.6M
↓ 14.21%
Total Liabilities
8.0M
↓ 7.99%
Q4 FY23Q/Q Change
Total Assets
14.6M
↑ 7.21%
Total Liabilities
7.9M
↓ 0.43%
FY18Y/Y Change
Operating Cash Flow
-12.4M
↑ 52.31%
Investing Cash Flow
-201.0K
↓ 101.1%
Financing Cash Flow
5.2M
↓ 16475.0%
FY19Y/Y Change
Operating Cash Flow
-11.7M
↓ 5.8%
Investing Cash Flow
-131.0K
↓ 34.83%
Financing Cash Flow
5.5M
↑ 4.81%
FY20Y/Y Change
Operating Cash Flow
-4.6M
↓ 60.82%
Investing Cash Flow
3.6M
↓ 2881.68%
Financing Cash Flow
1.0M
↓ 81.26%
FY21Y/Y Change
Operating Cash Flow
-3.4M
↓ 26.42%
Investing Cash Flow
388.0K
↓ 89.35%
Financing Cash Flow
3.3M
↑ 221.48%
FY22Y/Y Change
Operating Cash Flow
-4.2M
↑ 25.75%
Investing Cash Flow
-99.0K
↓ 125.52%
Financing Cash Flow
7.4M
↑ 123.58%
FY23Y/Y Change
Operating Cash Flow
-6.2M
↑ 44.82%
Investing Cash Flow
-258.0K
↑ 160.61%
Financing Cash Flow
2.5M
↓ 66.35%
Q3 FY22Q/Q Change
Operating Cash Flow
-1.8M
↑ 31.18%
Investing Cash Flow
-187.0K
↑ 713.04%
Financing Cash Flow
-178.0K
↓ 180.18%
Q4 FY22Q/Q Change
Operating Cash Flow
-348.0K
↓ 80.98%
Investing Cash Flow
34.0K
↓ 118.18%
Financing Cash Flow
-318.0K
↑ 78.65%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.4M
↑ 601.44%
Investing Cash Flow
-82.0K
↓ 341.18%
Financing Cash Flow
3.4M
↓ 1160.38%
Q2 FY23Q/Q Change
Operating Cash Flow
-215.0K
↓ 91.19%
Investing Cash Flow
-17.0K
↓ 79.27%
Financing Cash Flow
-135.0K
↓ 104.0%

Technicals Summary

Sell

Neutral

Buy

Sonoma Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals Inc
29.91%
1.54%
-78.83%
-97.46%
-97.42%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-1.26%
20.07%
49.07%
48.24%
66.16%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
2.79%
0.0%
2.67%
14.3%
14.3%
Zoetis Inc.
Zoetis Inc.
3.87%
-5.35%
0.73%
-1.62%
59.42%
Viatris Inc.
Viatris Inc.
-10.49%
9.3%
13.4%
-31.25%
-35.25%
Catalent, Inc.
Catalent, Inc.
-3.71%
35.8%
43.6%
-46.34%
16.03%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals Inc
NA
NA
0.0
0.0
-0.83
-0.19
NA
0.49
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
36.8
36.8
0.44
4.07
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.13
28.13
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
32.67
32.67
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.25
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals Inc
Buy
$3.1M
-97.42%
NA
-41.24%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.6B
66.16%
36.8
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.5B
14.3%
28.13
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$77.4B
59.42%
32.67
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.6B
-35.25%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$9.7B
16.03%
211.02
-28.44%

Institutional Holdings

  • Geode Capital Management, LLC

    0.23%

  • JPMorgan Chase & Co

    0.21%

  • HRT FINANCIAL LLC

    0.18%

  • State Street Corporation

    0.16%

  • Goldman Sachs Group Inc

    0.13%

  • Millennium Management LLC

    0.08%

Company Information

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal

Organization
Sonoma Pharmaceuticals Inc
Employees
9
CEO
Ms. Amy M. Trombly
Industry
Health Technology

Discover More

FAQs